2026-04-15 13:40:33

Weight-loss injections may benefit the liver.

Scientists have discovered that semaglutide – the active ingredient in blockbuster jabs used to treat obesity and type 2 diabetes – can directly improve liver health, even in patients who shed little or no weight.

The drug – sold under brand names such as Wegovy and Ozempic – mimics a gut hormone known as GLP-1.

While it is widely used to help people slim down, researchers at Toronto’s Sinai Health say it may also tackle metabolic dysfunction-associated steatohepatitis (MASH) – a serious liver disease linked to fat build-up.

The condition can lead to scarring and long-term damage.

Traditionally, weight loss has been seen as the main way to improve it – but the new findings challenge that idea.

Dr Daniel Drucker, a senior investigator involved in the study, said clinical trials had already hinted at something unusual.

He explained: “Patients who lose very little weight see the same reductions in liver inflammation and scarring as those who lose a great deal. Now we know why.”

Visit Bang Bizarre (main website)